# Editorial: Reviews in: multiple sclerosis and neuroimmunology

**Authors:** Omid Mirmosayyeb

PMC · DOI: 10.3389/fneur.2026.1746702 · Frontiers in Neurology · 2026-02-18

## Full-text entities

- **Diseases:** peripheral neuropathies (MESH:D010523), sensory or (MESH:D009477), autoimmune encephalomyelitis (MESH:D004681), axonal damage (MESH:D001480), Neuroimmunological disorders (MESH:D009358), cognitive impairment (MESH:D003072), autonomic dysfunction (MESH:D001342), MS (MESH:D009103), deficits (MESH:D009461), NMOSD (MESH:D009471), visual disturbances (MESH:D014786), autoimmune encephalitis (MESH:D020274), MOGAD (MESH:D003711), neurological damage (MESH:D020196), inflammation (MESH:D007249), CIDP (MESH:D020277), inflammatory, demyelinating, and neurodegenerative sequels (MESH:D019636), primary progressive (MESH:D018888), PPMS (MESH:D020528), fibrosis (MESH:D005355), neuroinflammation (MESH:D000090862), encephalitis (MESH:D004660), GBS (MESH:D020275), NMDAR (MESH:D060426)
- **Chemicals:** alemtuzumab (MESH:D000074323)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956508/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956508/full.md

---
Source: https://tomesphere.com/paper/PMC12956508